Atara Falls As PINTA Sinks In Phase II
This article was originally published in Scrip
Executive Summary
Atara Biotherapeutics Inc. fell 36.8% to $21 per share on Dec. 14 after the company suspended work on PINTA 745 for the reversal of peptide-energy wasting (PEW), leaving only two of the company's Christopher Columbus-themed drug candidates – previously in development by subsidiaries known as Nina and Santa Maria – afloat along with newer oncology and immunotherapy programs.
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.